Clinical Trial Update: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Envafolimab, a PD-L1 inhibitor, in combination with chemotherapy for biliary tract cancer, is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Envafolimab (envafolimab)

Snippet

Sponsor: 3D Medicines (Sichuan) Co., Ltd. | Conditions: Biliary Tract Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING